A security analysis is not yet prepared for this market.
The series is stated in the current share scale after splits; dividends are not included in the price
Rhythm Pharmaceuticals, Inc. (RYTM) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-06-30, revenue was 239.9m $, net income was -205.3m $. Incorporated in the United States.
This summary is compiled automatically from SEC filings and exchange data.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Rhythm Pharmaceuticals, Inc. (RYTM) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Rhythm Pharmaceuticals, Inc. (RYTM) on November 17, 2026 is $115.36, +7.33% on the day. Over 52 weeks the stock traded between $74.50 and $122.20; the price now sits 86% of the way up that range. Over the past year the price changed by +16.04%. Market capitalisation is $7.40 billion, rank 30 among 381 stocks of the same industry with a known capitalisation.
Rhythm Pharmaceuticals, Inc. trades on Nasdaq under the ticker RYTM. The company belongs to the Health care sector. The trading history on this page starts on 9 October 2017.
Over the past 52 weeks RYTM has traded between $74.50 and $122.20. As of 17 November 2026 the price stood 85.65% of the way from the 52-week low to the high.
Over one year RYTM shares rose 16.04%; over six months they rose 32.84%. Volatility over 90 days is 58.32%. Dividends are not included: this is price change only, as of 17 November 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 30.8, above the sector median of 3.6. Price to book is 71.8, above the sector median of 2.3. Calculated from reports for the period ending 30 June 2026.
Rhythm Pharmaceuticals, Inc. reported revenue of $240M and a net loss of $205M over the last four quarters. Net margin is −85.59%. Revenue changed by +53.51% year over year. Earnings per share are −$3.12. Market capitalisation is $7.4B.
RYTM has a return on equity of −199.40%, below the sector median of −40.58%. Return on assets is −46.96%, below the sector median of −30.08%. Operating margin is −83.62%, below the sector median of −20.96%.